[go: up one dir, main page]

WO2002022144A1 - Medicament chinois naturel a base de piper laetispicum c. dc et applications des extraits de piper laetispicum c. dc dans la preparation d'une composition pharmaceutique - Google Patents

Medicament chinois naturel a base de piper laetispicum c. dc et applications des extraits de piper laetispicum c. dc dans la preparation d'une composition pharmaceutique Download PDF

Info

Publication number
WO2002022144A1
WO2002022144A1 PCT/CN2001/001172 CN0101172W WO0222144A1 WO 2002022144 A1 WO2002022144 A1 WO 2002022144A1 CN 0101172 W CN0101172 W CN 0101172W WO 0222144 A1 WO0222144 A1 WO 0222144A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
chinese herbal
herbal medicine
preparation
loquat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/001172
Other languages
English (en)
Chinese (zh)
Inventor
Shengli Pan
Fugang Qian
Ezhuo Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to AU2002213750A priority Critical patent/AU2002213750A1/en
Publication of WO2002022144A1 publication Critical patent/WO2002022144A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention relates to extracting active ingredients from Chinese herbal medicine leaf medicine to make medicines, which are used for preventing and treating depression and mental disorders. Background technique
  • Kavacava is a new type of natural health medicine that has become popular in Europe, America and Japan in recent years. Used to relax tension, sedation and anti-depression. Its plant source is Piper methysticum Forst, which grows in the South Pacific island countries. 0
  • An object of the present invention is to provide a Chinese herbal medicine, a large leaf medicine Piper laetispicum C. DC, an extract thereof and a preparation method thereof.
  • Another object of the present invention is to use the above-mentioned extract as a raw material of a pharmaceutical preparation.
  • Still another object of the present invention is to provide the application of Chinese herbal medicine leaf medicine and its extract in the preparation of medicine for treating depression and mental disorders.
  • Large leaf Piper laetispicum C. DC is a Piper L. plant of the Piperaceae family, distributed in Guangdong, soiled Guangxi, and Hainan provinces. In the place of origin, it is used as an analgesic and blood swelling and analgesic agent for the treatment of bruises and bruises.
  • the research of the present invention finds that the extracts extracted from the ethanol and ethyl acetate of the large leaf have analgesic, sedative and antidepressant effects. Especially in terms of antidepressant effect, it is 2 to 3 times stronger than similar foreign products Kavakava.
  • An invention has been prepared by the following method.
  • the main ingredients are lactones, glycosides and alkaloids.
  • the lobular medicine and the extract thereof can be used as pharmaceutical raw materials to make preparations such as capsules, tablets, injections, oral liquids, and slow-release agents.
  • the large leaf extract (POS) of the present invention has obvious antidepressant effects, sedative and analgesic effects on mice.
  • the animal experiment method and results of the present invention are as follows-The kava kava used as a control in this experiment is a product of Nutratech. Rhizoma grandifolia extract is formulated with 2% Tween 80. Experimental animals: Kunming mice, male, 22-25g, 8 mice per group.
  • Antidepressant Forced swimming. Mice were randomly divided into groups and adapted to the environment for 1 day. The drug was administered orally on the second day. Half an hour after the administration, the mice were placed in a glass bottle with a diameter of 10 cm, a height of 30 cm, and a water depth of 15 cm at a water temperature of 2.4 ° C. Each mouse could only perform experiments once. The mice were separated from each other during the experiment. When the mouse was placed in a glass bottle, it began to swim exclusively, and when "despaired" it floated on the water. Use a stopwatch to record the continuous time within 6 minutes and the next 4 minutes.
  • mice were placed in a box with a diameter of 35cm and a height of 15cm, and a 5cm X 5cm box was drawn on the bottom. The mice were first allowed to acclimate to the environment for 3 minutes, and then the number of cells that the mice walked within 5 minutes was observed.
  • mice were injected intraperitoneally with 1% acetic acid 0.1ml 1 10g body weight. Observe the number of twists within 10 minutes after the first twist.
  • control group was administrated with an equal amount of 2% Tween 80 aqueous solution.
  • Compound 2 dihydropiperlonguminine dark white needle-like crystal, hardly soluble in water, easily soluble in organic solvents such as chloroform, acetone, ethyl acetate, etc. Melting point: m.p.90-95 "C, molecular formula CieHaiNOs, molecular weight 275, structural formula:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une plante médicinale chinoise, le piper laetispicum c. dc, ses extraits et le procédé de préparation d'un médicament naturel ainsi que la composition pharmaceutique ainsi obtenue. Les extraits de piper laetispicum c. dc sont les ingrédients de base permettant d'obtenir des comprimés, des compositions à injecter, des médicaments à libération lente, des capsules et des compositions. Cette plante médicinale chinoise et à ses extraits sont spécialement indiqués dans le traitement de dépressions.
PCT/CN2001/001172 2000-07-14 2001-07-12 Medicament chinois naturel a base de piper laetispicum c. dc et applications des extraits de piper laetispicum c. dc dans la preparation d'une composition pharmaceutique Ceased WO2002022144A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213750A AU2002213750A1 (en) 2000-07-14 2001-07-12 The uses of chinese herb piper laetispicum c. dc and its extract for the preparation of pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00119452.6 2000-07-14
CNB001194526A CN1137702C (zh) 2000-07-14 2000-07-14 中草药大叶蒟乙酸乙酯抽提物在制备精神类药物中的应用

Publications (1)

Publication Number Publication Date
WO2002022144A1 true WO2002022144A1 (fr) 2002-03-21

Family

ID=4587697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001172 Ceased WO2002022144A1 (fr) 2000-07-14 2001-07-12 Medicament chinois naturel a base de piper laetispicum c. dc et applications des extraits de piper laetispicum c. dc dans la preparation d'une composition pharmaceutique

Country Status (3)

Country Link
CN (1) CN1137702C (fr)
AU (1) AU2002213750A1 (fr)
WO (1) WO2002022144A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100436407C (zh) * 2003-03-20 2008-11-26 蒋毅 大叶蒟有效部位的制备及其在医疗、保健领域的应用
CN103063789A (zh) * 2011-10-19 2013-04-24 天士力制药集团股份有限公司 同时检测大叶蒟中12个酰胺类生物碱的液相分析方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100356940C (zh) 2004-12-01 2007-12-26 蒋毅 制备大叶蒟提取物的方法、提取物及其应用
CN102475746B (zh) * 2010-11-23 2015-05-06 天士力制药集团股份有限公司 大叶蒟有效组分的制备方法
CN113209165A (zh) * 2017-11-01 2021-08-06 苏州颐华生物医药技术股份有限公司 一种大叶蒟提取物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757506B1 (de) * 1977-12-22 1979-06-13 Haarmann & Reimer Gmbh Verfahren zur Herstellung von Piperonylidencrotonsaeureamiden

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757506B1 (de) * 1977-12-22 1979-06-13 Haarmann & Reimer Gmbh Verfahren zur Herstellung von Piperonylidencrotonsaeureamiden

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100436407C (zh) * 2003-03-20 2008-11-26 蒋毅 大叶蒟有效部位的制备及其在医疗、保健领域的应用
CN103063789A (zh) * 2011-10-19 2013-04-24 天士力制药集团股份有限公司 同时检测大叶蒟中12个酰胺类生物碱的液相分析方法

Also Published As

Publication number Publication date
AU2002213750A1 (en) 2002-03-26
CN1137702C (zh) 2004-02-11
CN1291481A (zh) 2001-04-18

Similar Documents

Publication Publication Date Title
US9186385B2 (en) Plant extract compositions for prevention and treatment of influenza
Kumar et al. Central nervous system activity of Syzygium cumini seed
WO2014094632A1 (fr) Composition pharmaceutique pour le traitement de céphalées et procédé de préparation correspondant
CN103432184B (zh) 牛蒡子提取物在制药或食品中的应用
CN104547826B (zh) 高良姜提取物治疗痛经的医药用途
CN110035763A (zh) 用于治疗寄生虫病的组合物及其方法
CN104815138A (zh) 一种枳实提取物、制剂及用途
CN101450127A (zh) 一种木瓜总酚酸提取物及其用途
CN1840166A (zh) 温胆汤现代中药口服制剂及其生产方法
WO2002022144A1 (fr) Medicament chinois naturel a base de piper laetispicum c. dc et applications des extraits de piper laetispicum c. dc dans la preparation d'une composition pharmaceutique
CN1985922A (zh) 一种治疗感冒的药物组合物及其制备方法
CN102178721A (zh) 绞股蓝混悬液、提取物在制备治疗抗抑郁症药物中的应用
CN106236895A (zh) 一种治疗咳嗽的中药及其制备方法
CN102858359B (zh) 一种含有醇溶性且非水溶性甘草提取物的药物组合物,及其药物制剂、制药用途、治疗方法和制备方法
CN101837044A (zh) 野生苦豆子全草提取方法和口腔药用组合物
Malviya et al. The phytochemical and pharmacological properties of Sarpagandha: Rauwolfia Serpentina
CN109674848A (zh) 一种甘草提取物的制备方法与用途
Shoukat et al. Phyllanthus emblica: Its Health Benefits and Phytochemistry; A Detailed Review
CN100581560C (zh) 一种治疗感冒的药物及其制备方法
Abiola et al. Counteract inflammatory properties of the purified ethanolic extract of Acrostichum aureum (Linn.) leaf
CN1843418B (zh) 治疗胃肠炎的中药提取物、其制备方法及含有该提取物的中药组合物
CN114404547B (zh) 一种扶正化瘀膏方及其应用
CN1686514A (zh) 治疗焦虑症、抑郁症的中药制剂及其生产方法
CN101134057A (zh) 含紫杉醇的天然植物提取物的复方药物及其抗癌应用
CN1265815C (zh) 一种治疗肺热咳喘、支气管炎的胶囊及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP